Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Total Liabilities (2021 - 2026)

bioAffinity Technologies has reported Total Liabilities over the past 6 years, most recently at $4.3 million for Q1 2026.

  • Quarterly Total Liabilities rose 4.28% to $4.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Mar 2026, up 4.28% year-over-year, with the annual reading at $3.7 million for FY2025, 5.84% down from the prior year.
  • Total Liabilities was $4.3 million for Q1 2026 at bioAffinity Technologies, up from $3.7 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $16.8 million in Q2 2022 and troughed at $775151.0 in Q2 2023.
  • The 5-year median for Total Liabilities is $3.4 million (2023), against an average of $4.7 million.
  • Year-over-year, Total Liabilities plummeted 95.38% in 2023 and then skyrocketed 315.83% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $1.1 million in 2022, then surged by 195.63% to $3.4 million in 2023, then grew by 16.2% to $3.9 million in 2024, then fell by 5.84% to $3.7 million in 2025, then grew by 16.31% to $4.3 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Total Liabilities are $4.3 million (Q1 2026), $3.7 million (Q4 2025), and $2.6 million (Q3 2025).